Assenagon Asset Management S.A. Has $533,000 Stock Holdings in Ocular Therapeutix, Inc. $OCUL

Assenagon Asset Management S.A. trimmed its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 76.5% during the third quarter, HoldingsChannel reports. The firm owned 45,600 shares of the biopharmaceutical company’s stock after selling 148,100 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Ocular Therapeutix were worth $533,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Nisa Investment Advisors LLC raised its stake in Ocular Therapeutix by 62.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,392 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 893 shares in the last quarter. Trust Co. of Vermont raised its position in shares of Ocular Therapeutix by 16.1% during the second quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 1,000 shares during the period. Marex Group plc bought a new position in shares of Ocular Therapeutix during the 2nd quarter valued at about $115,000. Finally, Rafferty Asset Management LLC lifted its holdings in shares of Ocular Therapeutix by 21.2% during the 2nd quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 2,343 shares in the last quarter. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Trading Down 0.2%

Shares of NASDAQ:OCUL opened at $12.71 on Friday. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44. The stock has a market capitalization of $2.71 billion, a PE ratio of -8.83 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78. The company’s 50-day moving average price is $12.28 and its two-hundred day moving average price is $11.67.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. The firm had revenue of $14.54 million during the quarter, compared to the consensus estimate of $14.57 million. Ocular Therapeutix had a negative return on equity of 86.33% and a negative net margin of 447.57%. On average, equities analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Robert W. Baird increased their target price on Ocular Therapeutix from $17.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, October 3rd. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 2nd. JMP Securities raised their price objective on shares of Ocular Therapeutix from $20.00 to $29.00 and gave the stock a “market outperform” rating in a report on Wednesday, October 1st. TD Cowen upped their target price on shares of Ocular Therapeutix from $14.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Piper Sandler increased their target price on Ocular Therapeutix from $21.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, October 3rd. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average target price of $22.56.

Insider Activity at Ocular Therapeutix

In related news, insider Peter Kaiser sold 9,653 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total transaction of $106,472.59. Following the transaction, the insider directly owned 194,440 shares of the company’s stock, valued at approximately $2,144,673.20. The trade was a 4.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Todd Anderman sold 11,132 shares of the firm’s stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $12.34, for a total value of $137,368.88. Following the sale, the insider directly owned 87,568 shares of the company’s stock, valued at $1,080,589.12. This represents a 11.28% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 31,287 shares of company stock worth $359,784. Insiders own 2.30% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.